Conclusion: The introduction of small molecule agents in the EU over recent years (upadacitinib and filgotinib) has provided new options for the treatment of RA, creating a shift in the switching arena from TNF cycling to more utilization of alternate mechanisms of action post first line therapy in favor of JAK inhibitors.
REFERENCES: None
Disclosure of Interests: Maxine Yarnall: None declared, Peter C. Taylor Consultant of: Received consulting fees from AbbVie, Biogen, Eli Lilly, Fresenius, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Nordic Pharma, Pfizer Inc, Roche, and Sanofi., Grant/research support from: Received research grants from Celgene and Galapagos., Phil Pouliot: None declared, Emily Hettel: None declared, Kara Murray: None declared
DOI: 10.1136/annrheumdis-2022-eular.5091

AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB

N. Inanc[1], K. Abacar[1], M. A. Ozturk[2], A. Tufan[2], H. Karadeniz[2], İ. Sari[3], G. Can[3], Y. Erez[3], Y. Pehlivan[4], E. Dalkılıç[4], T. Ocak[4], A. Cefle[5], A. Yazici[5], A. Senel[6], S. Akar[7], E. Durak Ediboglu[7], S. S. Koca[8], R. Piskin Sagir[8], S. Yılmaz[9], S. Gulcemal[9], Ö. Soysal Gündüz[10], C. S. Başıbüyük[11], S. Alkan[11], T. Y. Cesur[11], F. Onen[3]. *[1]Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; [2]Gazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; [3]Dokuz Eylül University Hospital, Department of Internal Medicine, Division of Rheumatology, Izmır, Turkey; [4]Bursa Uludag University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey; [5]Kocaeli University School of Medicine, Division of Rheumatology, Kocaeli, Turkey; [6]Kayseri University School of Medicine, Division of Rheumatology, Kayseri, Turkey; [7]Izmir Katip Celebi University Ataturk Training and Research Hospital, Division of Rheumatology, Department of Internal Medicine, Izmır, Turkey; [8]Firat University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Elazıg, Turkey; [9]Selcuk University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Konya, Turkey; [10]Manisa Celal Bayar University Hafsa Sultan Hospital, Department of Internal Medicine, Division of Rheumatology, Manisa, Turkey; [11]Pfizer Pharmaceuticals, Inflammation and Immunology, Istanbul, Turkey*

Background: Combination of MTX with a bDMARDs or tsDMARDs is considered the most effective treatment regimen currently available for patients with RA who have failed to respond to conventional DMARDs. However, approximately 30% of patients receive bDMARDs as monotherapy in daily clinical practice. Studies in the literature do not assess unintentional monotherapy in general. However, it is thought that some patients may switch to monotherapy unintentionally. In other words, some patients who are prescribed combination therapy switch to monotherapy without informing their physicians.
Objectives: To determine the rate of unintentional monotherapy in rheumatoid arthritis (RA) patients receiving tofacitinib and to evaluate tofacitinib survival rate.
Methods: This national, multicentre, retrospective study included patients' data from the TURKBIO Registry. Data on demographics, clinical characteristics, disease duration and activity, comorbidities, and treatment were analysed.
Results: Data of 231 RA patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to monotherapy of their own will (unintentional monotherapy); 21 were initially prescribed monotherapy and switched to combination therapy; 26 were initially prescribed monotherapy and continued to their therapies. The combination and unintentional monotherapy groups did not differ regarding remission rate assessed by DAS28-CRP (60.5% and 70%, respectively, p=0.328). The rate of comorbidities at the time of data retrieval was significantly higher in the unintentional monotherapy group compared with the combination group (83.3% vs. 60.3%, p=0.031). Presence of comorbidities was a significant factor affecting switching to monotherapy (p=0.039, Odds ratio: 3.29, 95% CI: 1.06-10.18). Drug survival rates of the unintentional monotherapy and combination groups did not differ. The median drug survival duration of tofacitinib was 27+ months with a 1-year and 4-year drug survival rates of 89.6% and 60.2%, respectively, in the unintentional monotherapy group.
Conclusion: Although 13.4% of the study population started monotherapy unintentionally, drug survival rates of the unintentional monotherapy and combination groups were not different. Comorbidity was an important factor affecting transition from combination therapy to monotherapy. This study was sponsored by Pfizer.
Disclosure of Interests: Nevsun Inanc: None declared, Kerem Abacar: None declared, mehmet akif ozturk: None declared, Abdurrahman Tufan: None declared, Hazan Karadeniz: None declared, İsmail Sari: None declared, gercek can: None declared, Yesim Erez: None declared, yavuz Pehlivan: None declared, Ediz Dalkılıç: None declared, Tuğba Ocak: None declared, Ayse Cefle: None declared, Ayten Yazici Grant/research support from: Ayten Yazici has received project grant from Roche Pharmaceuticals, Turkey., Abdurrahman Senel: None declared, Servet Akar: None declared, Elif Durak Ediboglu: None declared, Süleyman Serdar Koca: None declared, Rabia Piskin Sagir: None declared, Sema Yılmaz: None declared, Semral Gulcemal: None declared, Özgül Soysal Gündüz: None declared, Canberk Sami Başıbüyük Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey., Serdar Alkan Employee of: employee and shareholder of Pfizer Inc., Istanbul, Turkey., Teoman Yusuf Cesur Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey., Fatos Onen: None declared
DOI: 10.1136/annrheumdis-2022-eular.5102



Figure 1.

AB0421 ASSESSEMENT OF LIVER STIFFNESS IN RHEUMATOID ARTHRITIS PATIENTS UNDER METHOTREXATE

W. Lahmar[1], M. Slouma[1], G. Mohamed[2], R. Dhahri[1], L. Metoui[1], I. Gharsallah[1], N. Abdelli[2]. *[1]Military Teaching Hospital, Rheumatology, Tunis, Tunisia; [2]Military Teaching Hospital, Gastroenterology, Tunis, Tunisia*

Background: Methotrexate (MTX) is recommended as a first-line disease-modifying antirheumatic drug for treating rheumatoid arthritis (RA) in monotherapy or combinational therapy. A concern about MTX-related liver fibrosis in patients with rheumatoid arthritis (RA) is still unsolved.
Objectives: The aim of the study cutoff of cumulative dose discriminating patients with normal from those with abnormal liver stiffness.
Methods: We conducted a cross-sectional study including consecutive RA patients diagnosed according 2009 ACR-EULAR criteria. Liver stiffness (LS) was assessed by Fibroscan in the gastroenterology department by an experienced operator. The LS is measured in kilopascals (kPa). It is normal when < 6.2 kPa. Above this rate it is considered pathological. Substantial liver fibrosis was defined as liver stiffness of greater than 8 kPa. We collected the following parameters: age, disease duration, disease activity assessed by DAS28, cumulated dose of MTX and duration of this treatment, and the body mass index (BMI). Patients underwent blood testing exploring hepatic function: alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl tansferase (GGT), total bilirubin (TB), albumin (ALB) and prothrombin time (PT). Statistical analysis was performed using SPSS software.
Results: There were 18 men and 36 women. The mean age was 51.9 + 11.49 [22-83]. The mean BMI was 27.27 + 3.40. The mean disease duration 8.08 + 6.28 years. The mean DAS28CRP was 3.96 + 1.49. The mean cumulative dose of MTX was 3670 + 3432.61mg and mean MTX duration was 55.75 + 50.89 months. The mean of LS was 4.6 + 1.64 kPa. The means of the liver blood tests are as follows: AST 20.83 + 8.58 UI/L, ALT 19.60 + 9.39 UI/L, ALP 84.65 + 38.68UI/L, TB 9.50 + 4.79 UI/L, GGT 25.88 + 14.26UI/L, ALB 35.19 + 5.47 g/L, PT 94.60 + 9.02. Eight patients had abnormal LS values and two patients had advanced liver fibrosis. However, hepatic blood tests (AST, ALT, GGT, TB, ALB, PT) were normal in these patients. A correlation was found between LS and following parameters: cumulative dose of MTX (r: 0.347, p: 0.013), the methotrexate duration (r: 0.363, p: 0.010) and total bilirubin rate (r:0.390, p: 0.005). Receiver Operator Curve (ROC) analysis showed the cut-off point of cumulative dose of MTX with the best accuracy in distinguishing patients with normal LS from those with LS higher than 6.2 kPA was 7330 mg, with a sensitivity of 50% and specificity of 91.3% (air under the curve (AUC) value: 0.732 (p=0.03).
Conclusion: Our study showed that LS correlated to both MTX duration and cumulative dose. Patients with a cumulative dose of MTX higher than 7330 mg required a close follow up of liver elastometry and monitoring of hepatic function.
Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5224

Ann Rheum Dis: first published as 10.1136/annrheumdis-2022-eular.5102 on 23 May 2022. Downloaded from http://ard.bmj.com/ on November 3, 2022 at Bursa Uludag Universitesi. Protected by copyright.